Cardiac Safety Research Consortium

  • This field is for validation purposes and should be left unchanged.
Focused multiracial corporate business team people brainstorm on marketing plan financial report gather at office table meeting, diverse serious colleagues group discuss paperwork engaged in teamwork
Our Impact > Think Tanks

CSRC Annual Meeting: 10 Years of Excellence

7:30am-8:00am Breakfast

8:00am- 8:05am Welcome and Introduction- Philip Sager, MD (Stanford University)

8:05am-8:45am Plenary Session I: The future of drug and device development: balancing benefit and risk – Janet Woodcock, MD (FDA) (20min)

Moderators: Mitchell Krucoff, MD (Duke University Medical Center), Norman Stockbridge MD, PhD (FDA)

Discussion (20min)

8:45am-11:20am Session II: Role of public–private partnerships

Moderators- Ignacio Rodriguez, MD (Roche), Rick Turner, PhD, DSc (QuintilesIMS)

  • CSRC- What has been contributed over the last 10 years
    • Brief history of the CSRC and Overview of accomplishments and areas of impact – Mitchell Krucoff, MD (Duke University Medical Center)(20min)
      • Regulatory impact- QT and CIPA, anticoagulants for NOAC’s, CRF forms, Outcome Studies, White Papers
      • Relationships with other organizations (include DIA relationship, Cardio-Oncology, Pediatric CV Safety) and regions
    • Impact of public-private partnerships in cardiology- Norman Stockbridge, MD, PhD (FDA)(15min)
    • MDEpiNet: lessons learned- Jesse Berlin, ScD (Johnson & Johnson)(15min)
    • CTTI (Clinical Trials Transformation Initiative): lessons learned- Annemarie Forrest, RN, MS, MPH (Duke University Medical Center)(15min)
    • How can working together be enhanced?

Discussion (60min)

Lunch 11:20pm-12:30pm

12:30pm-2:00pm Session III: Updates on Think Tanks- Impact and what has occurred since

Moderators- Jonathan Seltzer, MD, MBA (ACI Clinical), Thomas Todaro, MD, (MedPace)

  • CV Outcomes Think Tank
    • CV Outcomes Think Thank and current status DM outcome trials White Paper- Rick Turner, PhD, DSc (QuintilesIMS)(15 min)
    • Mu-opioid receptor Advisory Committee Meeting- Peter Kowey, MD (Lankenau Medical Center)(15min)
    • Reversal agents for NOAC’s- Paul Reilly, PhD (Boehringer Ingelheim)(15min)

Discussion (45min)

Break: 2:00pm-2:10pm

2:10pm-3:15pm Session IV: Updates on Think Tanks Moderators: Philip Sager, MD (Stanford), Peter Kowey, MD (Lankenau Medical Center)

  • Prevention of Sudden Cardiac Death in the Young– Salim F. Idriss, MD, PhD (Duke University Medical Center)(15min)
  • Phase 1 ECG assessment – focus on Think Tank to a collaborative research study to ICH revision- Borje Darpo, MD, PhD (iCardiac Technologies)(10min)
  • CiPA Effort- Gary Gintant, PhD (Abbvie)(10min)

Discussion (30min)

3:15pm-4:15pm Discussion of potential future CSRC areas of focus and opportunities

Moderators- Theressa Wright, MD (Eli Lily), Mary Jane Geiger, MD (Regeneron)

  • Survey Results.

Panel Discussion

Panelist:

  • Mitchell Krucoff, MD (Duke University Medical Center)
  • Norman Stockbridge, MD, PhD (FDA)
  • Kaori Shinagawa, MD (PMDA)
  • Peter Kowey, MD (Lankenau Medical Center)
  • Philip Sager, MD (Stanford University)